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ABSTRACT
Background: Tumorigenesis is driven by stem cell (SC) overpopulation. Because 
ALDH is both a marker for SCs in many tissues and a key enzyme in retinoid acid (RA) 
signaling, we studied RA signaling in normal and malignant colonic SCs.
Hypothesis: RA signaling regulates growth and differentiation of ALDH+ colonic 
SCs; dysregulation of RA signaling contributes to SC overpopulation and colorectal 
cancer (CRC) development.
Methods: We analyzed normal and malignant colonic tissues and CRC cell lines 
to see if retinoid receptors (RXR & RAR) are exclusively expressed in ALDH+ SCs, 
and if RA signaling changes during CRC development. We determined whether RA 
signaling regulates cancer SC (CSC) proliferation, differentiation, sphere formation, 
and population size.
Results: RXR & RAR were expressed in ALDH+ colonic SCs, but not in MCM2+ 
proliferative cells. Western blotting/immunostaining of CRCs revealed that RA 
signaling components become overexpressed in parallel with ALDH overexpression, 
which coincides with the known overpopulation of ALDH+ SCs that occurs during, 
and drives, CRC development. Treatment of SCs with all-trans retinoic acid (ATRA) 
decreased proliferation, sphere formation and ALDH+ SC population size, and induced 
differentiation along the neuroendocrine cell (NEC) lineage.
Conclusions: Retinoid signaling, by regulating ALDH+ colonic CSCs, decreases SC 
proliferation, sphere formation, and population size, and increases SC differentiation to 
NECs. Dysregulation of RA signaling in colonic SCs likely contributes to overpopulation 
of ALDH+ SCs and CRC growth.
Implications: That retinoid receptors RXR and RAR are selectively expressed in 
ALDH+ SCs indicates RA signaling mainly occurs via ALDH+ SCs, which provides a 
mechanism to selectively target CSCs.
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INTRODUCTION
Stem cell (SC) overpopulation drives colorectal 
cancer (CRC) development and growth. Because 
aberrant regulation of SC dynamics likely contributes to 
SC overpopulation, understanding how colon SCs are 
regulated is important [1]. We discovered that aldehyde 
dehydrogenase (ALDH) is a marker for normal and 
malignant human colon SCs and tracks SC overpopulation 
during colon tumorigenesis [2]. Because ALDH is a key 
enzyme in the retinoic acid (RA) signaling pathway, and 
because aberrant RA signaling alters cell proliferation 
and differentiation that contributes to CRC progression 
[3–5], we studied RA signaling in normal and malignant 
colon SCs. Our long-term goal was to determine how RA 
signaling regulates SC dynamics and how dysregulation 
of RA signaling leads to CRC initiation and progression.
RA signaling is mediated by two nuclear retinoic 
receptor subtypes: the retinoic acid receptor (RAR) and 
the retinoic X receptor (RXR) [6]. As both RXR and RAR 
are involved in dimerization involving different RAR 
and RXR receptor subtypes, they are the mediators of 
transcriptional responses to stimuli from multiple kinds 
of signaling. Both RXR and RAR receptors interact with 
multiple co-activator and co-repressor proteins to promote 
increased cell stemness or cell differentiation [6–9].
Two of the most common, naturally occurring 
retinoic acid ligands that mediate cellular RA signaling 
are all-trans retinoic acid (ATRA) and 9-cis RA [6]. 
These ligands are known to have different affinity for 
RA receptors. Specifically, RAR subtypes have a higher 
affinity to and become activated by ATRA than other RA 
ligands [10, 11]. 9-cis RA binds to both RXR and RAR 
receptors but with higher affinity to RXR [10]. ALDH1, a 
SC marker, is a key enzyme of the RA signaling pathway 
that converts retinaldehyde to ATRA, a derivative of 
retinoic acid. Identifying the role of the RA signaling 
pathway in colonic SCs and alterations in RA signaling in 
CSCs might suggest novel targets for cancer therapeutics, 
particularly since RA agents, such as ATRA, are clinically 
available.
In the current study, we analyzed colon cancer 
cell lines and CRC patient tumor samples to determine 
if changes in key components of the RA pathway, 
particularly in RXR and RAR, occur during CRC 
development and progression. Other experiments were 
designed to determine: 1) if RA receptors (RXR & RAR) 
are selectively expressed in colonic SCs; 2) if RA signaling 
regulates stemness and maturation of colonic SC, and 3) 
if alterations in RA signaling occur during, and contribute 
to CRC development. Because NECs mainly reside 
in the crypt SC niche and can regulate the colonic SCs 
characteristics [12], we also determined if there was a link 
between RA receptor signaling and SC maturation toward 
a neuroendocrine cell (NEC) phenotype. Our immediate 
objective was to determine whether RA signaling regulates 
colonic SCs and if so, how dysregulation of RA signaling 
might lead to CRC progression.
RESULTS
Expression of RAR, RXR and ALDH in normal 
colonic epithelium (NCE) and CRC tissues
Expression of retinoid receptors RAR and RXR was 
analyzed in paraffin-embedded tissue sections of normal 
colonic tissue. We found that the cells staining positively 
for RAR and RXR were selectively located in the bottom 
1/3 of the colonic crypts, particularly in the SC niche. 
The majority of the ALDH1+ (85%), RAR+ (87%), and 
RXR+ cells (63%) were located in the SC niche (crypt 
levels 1-20; [2]). Co-staining for the SC marker ALDH1 
and retinoid receptors showed that the majority (>90%) 
of ALDH+ cells in the SC niche co-express ALDH1 with 
RAR or RXR (Figure 1A). In comparison, co-staining 
for ALDH and the cell proliferation marker MCM2 did 
not show any overlap and the staining patterns identified 
distinct cell types (Figure 1B).
To determine if expression of retinoid receptors 
(RXR and RAR) becomes altered during CRC 
development, immunostaining was also done on normal 
colonic epithelium (NCE) and CRC tissue samples. CRC 
tissue samples showed increased ALDH1, RAR, and RXR 
protein expression as compared to matching normal tissues 
(Figure 1C). We previously observed a similar alteration 
for ALDH1 overexpression in CRC progression [2].
Given that retinoid receptors and ALDH are key 
components involved in RA signaling, we also assessed 
other components of the retinoid signaling pathway 
using western blot analysis of matched NCE and CRC 
tissue samples. In parallel with increased ALDH1, RXR 
and RAR overexpression was seen in CRC as compared 
to NCE (Figures 1C & 2A, 2B). CRC samples also 
showed increased expression of CYP26A1 and CtBP1, 
both of which are downstream of ALDH in the retinoic 
acid pathway (Figure 2C). Thus we observed increased 
expression of retinoid receptors, as well as of other key 
components of the RA pathway in CRC tissues.
Expression of RAR, RXR, ALDH and retinoid 
signaling components in CRC cell lines
To understand the relationship between ALDH1 
and retinoid receptors, an in vitro tissue culture system 
was employed. Based on previous screening of colon 
cancer cell lines for ALDH1 expression and ALDH 
activity, we chose HT29 and SW480 cells [13]. These two 
cell lines were screened for protein expression of RAR, 
RXR, ALDH1, CYP26A1 and CtBP1 (Figure 2A-2C). 
Western blot analysis showed that both cell lines express 
relatively high levels of all components of the retinoid 
signaling pathway (Figure 2A-2C). Immunocytochemical 
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staining of HT29 and SW480 cells showed increased 
RAR and RXR-alpha expression in both lines but SW480 
cells had relatively more retinoid receptor positive cells 
(Supplementary Figure 1).
To further analyze protein expression of RXR and 
RAR in the CRC cell lines, ALDH+ cells and ALDH- cells 
were sorted from the HT29 and SW480 cells using the 
ALDEFLUOR assay. Western blot analysis of HT29 cells 
showed increased expression of both retinoid receptors 
in ALDH+ cells as compared to ALDH- cells (Figure 3). 
This is not as clear in the case of SW480 cells. Even so, 
we show by immunofluorescence analysis of primary 
colonic tissues that there is co-staining of both RAR and 
RXR with ALDH1A1 (see Figure 1).
Effect of ATRA on cell proliferation
To investigate effects of RA ligands on cell growth, 
we treated colon cancer cell lines (HT29 and SW480) with 
ATRA. The IC50 values were 10 μM ATRA for HT29 cells 
and 100 μM ATRA for SW480 cells, as we previously 
reported [14, 15].
In time course experiments, we found that cell 
proliferation in both lines significantly decreased when 
exposed to ATRA (Figure 4A, 4B). Thereafter, HT29 
and SW480 cells were treated with the IC50 values of 
ATRA in order to assess effects of RA signaling on the SC 
population via the ALDEFLUOR assay, neuroendocrine 
cell differentiation, and on anchorage-independent growth.
Effect of ATRA on sphere formation
Given these effects of RA signaling on proliferation, 
SC population size and NEC differentiation, we next 
investigated whether ATRA treatment affects sphere 
formation. We surmised that if the cells are induced to 
differentiate by ATRA treatment, then sphere formation 
should be reduced. Indeed, HT29 cells pre-treated with 
ATRA resulted in significantly fewer spheres after four 
days of pre-treatment (Figure 4C). The size of the spheres 
formed by HT29 cells, as measured by sphere diameter, 
was not significantly altered at any time point of pre-
treatment (Supplementary Figure 2). ATRA pre-treatment 
of SW480 cells also resulted in significantly fewer spheres 
as compared to controls (Figure 4C). Similar to HT29 
cells, SW480 cells formed spheres of similar size after 
treatment, as compared to the controls (Supplementary 
Figure 2). A representative image of the spheres formed 
for both HT29 and SW480 cells are shown in Figure 4D.
Effect of ATRA on the ALDH positive SC 
population size
Because RA receptors appear to be selectively 
expressed in ALDH+ SCs, we investigated whether the 
addition of exogenous ATRA would specifically change 
the ALDH+ SC population size. Both cell lines showed 
a significant decrease in ALDEFLUOR+ cells. This 
decrease occurred after two days of ATRA treatment of 
HT29 cells (Figure 5A), and after four days of ATRA 
treatment of SW480 cells (Figure 5B).
Effect of ATRA on differentiation of SCs into 
NECs
Because one way to characterize SCs is by their 
ability to differentiate into various cell lineages, we 
analyzed the effects of ATRA on differentiation into 
Figure 1: RAR and RXR-alpha retinoid receptors co-stain with ALDH1 but not with MCM2. Normal colonic crypt 
specimens from paraffin embedded tissue sections were stained which showed co-localization of retinoid receptors with the colonic SC 
marker ALDH1 (Images in Panel A), but not with the proliferating cell marker MCM2 (Images in Panel B). To appreciate cell localization 
of the signal, all single channels are also shown in black and white and merged channels are shown in color at higher magnification. Images 
in Panel (C) show staining (red) for retinoid receptors in colon tumors compared to normal colonic epithelium.
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NEC cells. We did this by western blot analysis for 
expression of NSE and CgA proteins, both of which are 
universal markers for NECs. Our previous publication 
showed that there are differential levels of expression 
of NE markers between HT29 and SW480 cells, and 
that is why different markers can be used to capture the 
majority of NE cells in a particular cell line [12]. We also 
observe, by immunofluorescence staining, co-expression 
of retinoid receptors with CgA in normal colonic crypt 
cells (Supplementary Figure 3) We found that ATRA 
Figure 2: CRC tissue and CRC cell lines express higher levels of ALDH1 and retinoid receptors than normal colonic 
tissue sections. (A) Cell lysates were collected and equal protein concentrations were run on an SDS-PAGE gel and in western blot 
analyses. The representative images show increased expression of retinoid signaling pathway proteins and ALDH1 in tumor tissues and 
HT29 and SW480 CRC cell lines, as compared to matched normal tissues. (B) Densitometry on western blot analysis represents the average 
fold change values with increased expression of RAR in tumor tissues and CRC cell lines, as normalized to the normal colonic epithelium. 
The densitometry on western blot analysis represents the average fold change values of RXR in the tumor tissues and CRC cancer cell 
lines, as normalized to the normal colonic epithelium. This experiment was done in triplicate and error bars represent ± SEM, * p < 0.05. 
(C) Representative western blot images show differential expression of retinoid signaling pathway proteins CtBP1 and CYP26A1, between 
HT29 and SW480 cells, and these proteins are almost absent in normal colonic epithelial tissues as compared to the matched tumor tissues.
Figure 3: RAR and RXR receptor protein expression in ALDH+ and ALDH- cell populations. ALDH+ and ALDH- cells 
were analyzed by the ALDEFLUOR assay and sorted as separate populations using the BD FACSAria II Flow Cytometer. Sorted cells were 
pelleted and protein was extracted to run on an SDS-PAGE gel and in western blot analysis. Both RAR and RXR protein expression was 
analyzed on the sorted (A) HT29 cells and (B) SW480 cells. The data represents the average densitometry values of each sample probed 
for RAR or RXR and normalized to the corresponding actin. The western blot images are representative blots from one experiment done 
on sorted ALDH- and ALDH+ cells from HT29 and SW480 cells and probed for RAR and RXR. Three independent sets of sorts were 
performed and analyzed; error bars represent ± SEM.
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treatment of HT29 cells led to a significant increase in 
NSE expression after 4 days of ATRA treatment (Figure 
5C). SW480 cells exhibited a significant increase in CgA 
expression upon ATRA treatment (Figure 5D). These 
increases in ATRA-induced SC differentiation into NECs 
occurred in parallel with the decrease in cell proliferation 
and the decrease in size of the ALDH+ SC population.
Effect of CYP26A1 inhibitor liarozole 
dihydrochloride on HT29 and SW480 cells
Because of the effects of ATRA on ALDEFLUOR+ 
cells, NEC differentiation, cell proliferation and sphere 
formation, we analyzed another component of the RA 
signaling pathway – CYP26A1 [16, 17]. As shown 
in Figure 7, CYP26A1 is an enzyme that degrades 
intracellular levels of ATRA and in cancerous cells, 
CYP26A1 is significantly elevated which fools the cell 
in thinking there are extremely low levels of ATRA. 
In turn, the cancerous cell produces more ALDH by 
increased metabolism of retinal into ATRA. Our final test 
was to inhibit CYP26A1, by adding exogenous liarozole 
dihydrochloride, and measure changes in ALDEFLUOR+ 
cells, cell proliferation, and sphere formation. After 
treatment with CYP26A1 inhibitor, we saw a decrease in 
cell proliferation for both cell lines, in a dose dependent 
manner (Figure 6A). In addition, there was a decrease 
in sphere formation in a dose dependent manner under 
anchorage independent conditions (Figure 6B). Finally, 
when HT29 and SW480 cells were treated with a low and 
high concentration of CYP26A1 inhibitor, there was a 
decrease in the ALDEFLUOR+ cells (Figure 6C). Overall, 
the similar trends and results were seen with the addition 
of exogenous ATRA and with the inhibition of CYP26A1.
DISCUSSION
A key finding is that RA signaling mainly occurs 
through ALDH+ SCs. This conclusion stems from our 
observation that RXR, RAR are selectively expressed in 
ALDH+ SCs. For example, our analysis of colonic tissues 
showed that cells staining positively for RAR and RXR 
were primarily located in the SC niche at the crypt bottom, 
where these cells co-stained with ALDH1. Conversely, 
retinoid receptors did not co-stain with MCM2, a marker 
for proliferating non-SCs. Our analysis of CRC cell lines 
also shows that ALDEFLUOR+ cells, which are SCs, 
tend to have higher levels of RAR and RXR. That RA 
signaling mainly occurs in ALDH+ SCs, also suggests that 
RA signaling regulates colonic SC dynamics.
Figure 4: ATRA treatment of both HT29 and SW480 colon cancer cell lines inhibited cell proliferation and decreased 
sphere formation. (A) HT29 and (B) SW480 cells were treated with the IC50 values of ATRA over a time course and ATRA treatment 
decreased cell proliferation over time. Cells were trypsinized from each well at each time point and counted using trypan blue exclusion. 
Cell number at each time point was plotted on the graphs for these experiments. This experiment was done in quadruplicate and error bars 
represent ± SEM, * p < 0.05. (C) Cells were serum starved for 24 hours and then treated with the IC50 value of ATRA for the designated 
time points for each cell line (see Materials and Methods). Then single cells were plated for soft agar assay to measure sphere formation 
after 10 days. ATRA treatment significantly decreased the number of spheres formed in HT29 and SW480 cells. (D) Representative images 
of sphere formation are shown from the last time point of ATRA treatment for each cell line. The numbers of spheres were counted from 
four wells of each replicate experiment. Experiments were performed in triplicate and error bars represent ±SEM, * p < 0.05. Images were 
taken on a phase-contrast microscope using the brightfield setting under a 10x objective.
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To understand how regulation of ALDH+ SC 
dynamics might occur, we considered known mechanisms 
by which ALDH levels are controlled in the RA signaling 
pathway (Figure 7). Specifically, ALDH expression is 
regulated via a feedback mechanism involving intracellular 
ATRA [18–20]. In this mechanism, an increased ATRA 
concentration leads to feedback inhibition of ALDH1 
expression, while decreased ALDH activity decreases 
conversion of retinaldehyde to RA, which reduces the 
intracellular ATRA level and lowers activation of RA 
receptors. Conversely, a decreased ATRA concentration 
produces the opposite response and generates positive 
feedback to increase ALDH expression [18]. This feedback 
mechanism also involves other components downstream 
of ALDH in the RA pathway, particularly CYP26A1 
and CtBP1. CYP26A1 is a cytochrome P450-associated 
enzyme that metabolizes RA, breaking it down into 4-OH-
RA or 4-OXO-RA [16, 17]. CtBP1 is a transcriptional 
corepressor which acts as a repressor of the RAR/RXR/
RARE transcriptional complex. Knowing the mechanisms 
by which ALDH levels are controlled in the RA signaling 
pathway, also helps us to understand how dysregulation of 
the dynamics of ALDH+ SCs might occur.
Indeed, another key finding is that during CRC 
development, the mechanisms that control ALDH levels 
become dysregulated. For example, our immunostaining 
and western blot analyses of matched NCE and CRC 
tissue samples revealed that RXR and RAR become 
overexpressed in parallel with increased ALDH. Our 
analysis of CRC lines showed results similar to those seen 
for patient tumor samples. Specifically, western blot and 
immunocytochemical analysis of SW480 and HT29 cells 
showed increased expression of RA receptors, RAR and 
RXR, as well as increased expression of CYP26A1 and 
CtBP1. That RA signaling components are overexpressed 
in CRC cells and tissues suggests that dysregulation of 
the mechanisms that control ALDH+ levels contributes to 
overpopulation of ALDH+ CSCs in CRC.
While our results indicate that the mechanisms that 
control the dynamics of ALDH+ SCs appear dysregulated 
in CRC cells, we wanted to see if RA signaling is still 
functional in CSCs and whether induction of RA signaling 
can inhibit the growth of ALDH+ CSCs. Because 
CSCs appear to contain the necessary components for 
RA signaling, we determined whether RA signaling 
regulates CSC phenotypes globally – at the level of cell 
Figure 5: ATRA treatment of HT29 and SW480 cells decreased the percentage of ALDH+ cells and increased NSE and 
CgA protein expression. (A) The HT29 cells were treated with 10 μM of ATRA and showed a significant decrease of percent ALDH+ 
cells at day 2. (B) The SW480 cells were treated with 100 μM of ATRA and showed a significant decrease of percent ALDH+ cells at day 
4. Note: the decrease in ALDEFLUOR+ cells in DMSO controls is attributed to the decrease in proportion of ALDH+ cells that occurs due 
to increased cell density of CRC cells that occurs over time in culture [13]. (C) In our studies on differentiation, HT29 cells demonstrated a 
significant increase in NSE expression after 4 days of ATRA treatment. (D) SW480 cells demonstrated a significant increase in CgA at day 
8 of ATRA treatment. ATRA treatment of the CRC cell lines induced neuroendocrine cell differentiation based on the protein expression 
of two broad neuroendocrine markers. All western blot data (C and D) represent the average densitometry values of each sample probed 
for NSE or CgA and normalized to the corresponding actin. The western blot images are representative blots from one experiment done 
on HT29 and SW480 ATRA treated cells and probed for NSE and CgA. All experiments were done in triplicate and error bars represent 
±SEM, * p < 0.05.
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Figure 6: CYP26A1 inhibitor liarozole treatment of HT29 and SW480 colon cancer cell lines decreases cell proliferation, 
sphere formation and ALDH+ CSCs. (A) HT29 and SW480 cells treated with liarozole dihydrochloride inhibited cell proliferation in 
a dose-dependent manner. Cells were trypsinized from each well at each time point and counted using trypan blue exclusion. The average 
percent of control was plotted on the graphs for these experiments. This experiment was done in triplicate and error bars represent ± SEM, 
* p < 0.05. (B) HT29 cells were treated with liarozole dihydrochloride (0-500 μM) for three days and plated as single cells to measure 
colonosphere formation. With an increase in liarozole dihydrochloride concentrations, the number of colonospheres formed decreased. This 
experiment was done in triplicate and error bars represent ± SEM, * p < 0.05. Because SW480 cells demonstrate poor sphere formation, they 
were not assayed. (C) HT29 and SW480 cells were treated with a low and high dose of liarozole dihydrochloride and ALDEFLUOR assay 
was performed to measure changes in ALDH+ population of cells. With the high dose of liarozole dihydrochloride, there is a significant 
decrease in the percent ALDH+ cells, in the SW480 cells and a decreasing trend in the HT29 cells. This experiment was done in triplicate 
and error bars represent ± SEM, * p < 0.05.
Figure 7: A comparison of normal and malignant colon tissues reveals differences in the expression of several key 
components in the retinoic acid (RA) signaling pathway. In the conversion of retinol to retinal a feedback regulatory mechanism 
normally maintains homeostatic levels of ALDH (the enzyme that metabolizes retinal into all-trans retinoic acid - ATRA). Through this 
mechanism, ALDH levels are tightly controlled by intracellular levels of retinoic acid agonists, particularly ATRA [18]. Intracellular 
ATRA levels are maintained by the enzyme CYP26A1 which catalyzes ATRA degradation. Specifically, RA signaling regulates ALDH 
via the binding of ATRA to retinoic acid receptors RXR and RAR that transcriptionally control ALDH gene expression. In tumor cells, 
several components of this pathway are increased, including ALDH, CYP26A1 and CtBP1. Increased ALDH in tumors can be explained 
by the feedback mechanism whereby increased CYP26A1 enzyme activity leads to ATRA degradation, and decreased ATRA levels then 
lead to increased ALDH via feedback controls. Specifically, decreased ATRA leads to less RA signaling through RXR- and RAR-based 
transcriptional control of ALDH. Moreover, we found that tumor cells have increased CtBP1, which acts as a transcriptional repressor of 
the RAR/RXR/RARE transcriptional complex. Transcriptional repression by CtBP1 not only leads to increased ALDH expression, but also 
up-regulates expression of genes that promote cell cycling.
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proliferation, CSC population size, sphere formation, and 
differentiation. We did this by treating HT29 and SW480 
cells with ATRA. In both time course and dose response 
experiments, ATRA treatment decreased cell proliferation 
of both cell lines. We also observed that ATRA 
substantially decreased the proportion of ALDEFLUOR+ 
cells in both cell lines. This finding indicates that the 
decrease in cell proliferation induced by RA signaling is 
due to inhibition of growth of the ALDH+ SC population.
That ATRA induced a decrease in cell proliferation, 
suggested that it was inducing differentiation. Hence, 
we determined whether activation of RA receptor 
signaling by ATRA induced SC differentiation toward a 
NEC phenotype. We chose to specifically analyze NEC 
differentiation since most crypt NECs reside adjacent to 
SCs in the SC niche [12, 21]. Indeed, we observed that 
differentiation toward a NEC lineage was induced in both 
HT29 and SW480 cell lines upon treatment with ATRA. 
The promoting effect of ATRA on NEC differentiation 
in CRC cells is consistent with the fact that ATRA also 
decreased ALDH+ SC population size.
Since ATRA was found to decrease SC population 
size and induce differentiation, we surmised that ATRA 
would also reduce SC colony growth or self-renewal. 
Hence we treated SW480 and HT29 cells with ATRA 
and assessed their sphere formation in soft agar assays. 
Indeed, ATRA-treated HT29 and SW480 cell lines caused 
a decrease in the number of spheres formed, although no 
significant changes occurred in the sizes of the spheres. 
Our findings that ATRA treatment decreases sphere 
numbers can be explained by our results showing that 
ATRA reduces ALDH+ SC population size and ATRA 
increases SC differentiation, which indicates that after 
being induced to differentiate by ATRA, fewer SCs exist 
that can generate spheres.
Overall, we have shown that ATRA treatment affects 
several CSC characteristics and functions. Specifically, 
treatment of CRC cells with ATRA (i) inhibited 
proliferation, (ii) decreased ALDH+ SC population size, 
(iii) induced differentiation of SCs along the NEC lineage, 
and (iv) reduced sphere formation. These data indicate that 
RA signaling is functional in colonic CSCs and induction 
of RA signaling can inhibit the growth of ALDH+ CSC 
by promoting their differentiation along the NEC lineage.
Our finding that SC signaling components are 
overexpressed and ALDH+ cells are overpopulated 
in CRC raises the question: How do alterations in RA 
signaling pathway components occur in CRC? One answer 
is that it is due to mutation of the adenomatous polyposis 
coli (APC) gene, which frequently occurs in CRC and is 
known to drive CRC growth and development. Wildtype 
APC protein is known to bind to CtBP1 and beta-catenin, 
and induce degradation of both proteins. In situations 
where APC is mutated, cells have impaired ability to 
degrade beta-catenin, which increases TCF4 signaling 
and proliferation. In the case of CRC, where APC is often 
mutated, CtBP1 expression levels would also be predicted 
to be elevated, as our results demonstrate. Overexpression 
of CtBP1 has also been shown to occur in adenomas 
from familial adenomatous polyposis patients who are 
hereditary colon cancer patients carrying germline APC 
mutations [22–24]. Thus, APC mutation likely contributes 
to upregulation of at least two key components of the RA 
signaling pathway.
Another question arises: How might dysregulation of 
RA signaling in colonic SCs contribute to overpopulation 
of colonic SCs that drives CRC development and growth. 
One explanation for how ALDH becomes overexpressed 
is based on changes in CYP26A1 and CtBP1 levels when 
viewed in the context of the RA pathway (Figure 7). In 
CRC cells, increased levels of CYP26A1 should decrease 
intracellular ATRA which, via feedback regulation, would 
increase ALDH expression. In fact, when a CYP26A1 
inhibitor was added to HT29 and SW480 CRC cell lines, 
there was a decrease in ALDEFLUOR+ cells, a decrease in 
cell proliferation and decrease in sphere formation (Figure 
6). Additionally, increased levels of CtBP1 will inhibit 
normal cell differentiation and upregulate cell cycling 
genes, which should also increase ALDH expression. 
Thus, a change in the expression of key components 
of the RA pathway in CRC cells likely contributes to 
the overpopulation of ALDH+ SCs and diminishes cell 
differentiation.
Other factors might also affect the ALDH+ SC 
population size. For example, expression of different 
ALDH isoforms may be a factor. Indeed, it has been 
reported that specific ALDH isoforms, such as ALDH1A1, 
ALDH1A2, ALDH1A3 and ALDH8A1, play a regulatory 
role in the initiation and progression of CRC [25]. We 
also showed that the pattern of ALDH isoform expression 
changes based on CRC cell density [13]. Changes in 
expression of different ALDH isoforms might influence 
the ALDH+ SC population size because the various 
isoforms have different substrate specificities for RA 
ligands that could induce changes in RA metabolism 
and affect the feedback control of ALDH levels. Thus, 
in future studies, as more information becomes available 
about these factors, it will be important to understand how 
they relate to control of ALDH+ SCs based on the RA 
signaling pathway (Figure 7).
MATERIALS AND METHODS
Immunofluorescence
Human colonic tissue sections were analyzed by 
imunofluorescence as we previously described [2]. Briefly 
we used anti-ALDH1 (BD Pharmingen, Franklin Lakes, 
1:50), anti-RXR-alpha (Santa Cruz, 1:50), anti-RAR-alpha 
(Santa Cruz, 1:50) and anti-MCM2 (Abcam, Cambridge 
1:100) as primary antibodies. The use of human tissues 
was approved by Institutional Review Boards of Thomas 
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Jefferson University and the Christiana Care Health 
Services, Inc (FWA00006557).
Cell culture
HT29 cells obtained from the American Type 
Culture Collection (ATCC; Manassas, VA) were grown in 
monolayer cultures and maintained in McCoys medium 
(GIBCO/Life Technologies) supplemented with 5% fetal 
bovine serum (FBS), 100 units/mL penicillin and 100μg/
mL streptomycin (P/S). SW480 cells obtained from 
ATCC were maintained in Leibovitz’s 15 (L-15) medium 
(GIBCO/Life Technologies) supplemented with 5% 
FBS and Penicillin/Streptomycin. All cell cultures were 
maintained at 37°C in humidified air at 5% CO2. Culture 
medium for all cell lines was changed every 48 hours. 
The cell lines were routinely tested for mycoplasma using 
a Universal mycoplasma detection kit (ATCC), and all 
experiments were carried out with cells cultured within 
eight - ten passages before earlier freeze down were 
brought up and used in additional experiments.
Immunocytochemistry (ICC)
ICC was done using SW480 and HT29 cells 
between passages 6-10. ICC was done in 8-well chamber 
slides from Lab tek II. SW480 and HT29 cells were fixed 
with 4% paraformaldehyde for 40 minutes and then, based 
on the antibody used the protocol changed. For ALDH1, 
the cells were then blocked with 1% BSA, 10% serum, 
0.2% triton and PBS. For RXR alpha and RAR alpha, 
0.2% triton extraction for 20 minutes was done first and 
the cells were then blocked with 1% BSA, 10% BSA and 
PBS. Blocking was done overnight at 4 degrees, followed 
by overnight primary antibody incubation at 4 degrees. 
Primary antibody was washed off using blocking buffer 
three times for 10 minutes each time. Secondary antibody, 
Alexa flour goat anti-rabbit, was used at a dilution of 
1:1000 and incubated at room temperature for 1.5 hours. 
After incubation with secondary antibodies, three washes 
were done with blocking buffer for 10 minutes. Cells were 
dried and later stained with SlowFade® Gold antifade 
DAPI and sealed with coverslips.
Protein extraction and western blots
Cells were trypsinized, pelleted and lysed with 
RIPA buffer (0.1% triton, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris HCl and 150 mM NaCl). Protease 
inhibitor was added to the RIPA buffer just before protein 
extraction. Cells were then vortexed to break up the 
pellet and incubated on ice for 30 minutes. Western blot 
analysis was done for HT29 cells, SW480 cells, and three 
matched (patient normal and patient tumor) pairs of tissues 
samples. Normal human colon samples and carcinoma 
samples were obtained from Christiana Care Hospital after 
patient consent under an approved IRB protocol. SDS-
PAGE was done using polyacrylamide gels (10%; Lonza) 
and a Bio-rad gel electrophoresis apparatus (2 hours at 
120 volts). Protein concentrations were determined using 
BCA protein assay kits (Pierce, cat # 23227). Protein 
was transferred to a PVDF membrane (0.45μm, Thermo 
Scientific, cat # 88518). For analysis of ALDH1 (BD 
Transduction Labs, cat # 611195), RXR-alpha (Abcam, 
Cambridge, MA), CtBP1(Abcam), Neuron specific 
enolase (NSE) (Novus Biologicals, cat# NB-110-58870) 
and CgA (Abcam), membranes were blocked with 3% 
BSA in Tris-Buffered Saline with 0.1% Tween 20 (TBST) 
overnight at 4°C on a shaker. For CYP26A1 (Abcam) 
and RAR-alpha (Santa Cruz Biotechnology Inc, Dallas, 
TX) membranes were blocked with 5% milk overnight at 
4°C on a shaker. Both primary and secondary antibodies 
(1:20,000) were prepared in 3% BSA in TBST for 
ALDH1 (1:300), RXR-alpha (1:500), CtBP1 (1:500), NSE 
(1:10,000) and CgA (1:1000), and in 5% milk in TBST 
for CYP26A1 (1:500) and RAR-alpha (1:800). Primary 
antibody incubation was done at 4°C overnight and then 
membranes were washed three times with 0.1% TBST for 
10 minutes. Secondary antibody incubation was done for 
1 hour at room temperature on a shaker and then washed 
three times with 0.1% TBST for 10 minutes. SuperSignal 
West Dura Chemiluminescent Substrate (Thermo Fisher 
Scientific; cat# 34075) was used to detect horseradish 
peroxidase (HRP) activity and blots were imaged using 
the Syngene imaging system (Syngene, Frederick, MD). 
Densitometry was done using the GeneTools software 
(Syngene).
ALDEFLUOR assay
Theprotocol followed the manufacturer instructions 
(STEMCELL Technologies, Vancouver, BC, CANADA) 
with previously described modifications [12, 13]. Briefly, 
cells were grown to 80% confluence and detached using 
0.25% Trypsin-EDTA (Fisher Scientific). Cells were 
incubated for 40 minutes at 37°C with ALDEFLUOR 
reagent. Cell were resuspended in 500 μL ALDEFLUOR 
buffer and transferred to a BD round bottom tube using a 
50 μm cell strainer (BD Biosciences) and analyzed on a 
BD FACSAria II Flow Cytometer.
Cell proliferation
All cells were plated at a concentration of 20,000 
cells/well of a 24 well plate (four wells per cell line). 
Medium was replaced every other day. Cells were detached 
using 0.25% Trypsin-EDTA (Life Technologies) at days 
1, 3 and 5, and counted manually with a hemocytometer. 
Cells were mixed in a 1:1 ratio with Trypan blue (Fisher 
Scientific) so reported cell counts include the total cell 
numbers. This was repeated three times and average 
values were graphed.
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Time course for ATRA
SW480 and HT29 cells were plated at 100,000 cells/
well of a 6 well tissue culture plate. Cells were incubated 
for 24 hours to allow attachment and then serum starved 
for 24 hours. At the time of treatment, cells were 40-50% 
confluent. SW480 cells were treated with 100 μM ATRA 
and HT29 cells were treated with 10 μM ATRA. The IC50 
values used for these experiments have been published 
by our lab previously [14, 15]. These concentrations 
were determined from the dose response curves for each 
cell line for each drug. SW480 and HT29 cells were 
treated for the specified number of days given in results. 
DMSO (0.1%) was used as a vehicle control for ATRA-
treated cells. Cells were counted at each time using a 
hemacytometer and trypan blue exclusion. Medium with 
ATRA was changed every 2 days. Each experiment had 
three replicates of drug treatment and three of vehicle. The 
final time course graph was plotted based on the average 
of three individual experimental sets.
Dose curve for liarozole dihydrochloride
SW480 and HT29 cells were plated at 100,000 cells/
well of a 6-well tissue culture plate. Cells were incubated 
for 24 hours to allow attachment and them serum starved 
for 24 hours. At the time of treatment, cells were 40-50% 
confluent. HT29 and SW480 cells were treated with either 
vehicle control (distilled water – 0 μM), or CYP26A1 
inhibitor (Liarozole 1μM, 10μM, 50μM, 100μM, 500μM) 
for 72 hours [16, 17]. Cells were trypsinized and counted 
at each concentration, using a hemocytometer and trypan 
blue exclusion. Experiments were done in quadruplicate 
and all p-values were determined as a percent of control 
(treated cells vs untreated cells (vehicle control)).
Soft agar assay for spherogenic potential
This assay was performed as we previously 
published [15]. Briefly, low-melting agar (2%) and 
McCoys medium containing 10% FBS (v/v), 100 U/ml 
penicillin (P) and 100μg/ml streptomycin (S) in 10 mM 
citrate buffer were mixed in a 1:1 volume ratio, yielding 
a final concentration of 1% agar-media solution. This 
solution was poured into each well of a 24 well plate 
(Griener, Monroe, NC) and allowed to solidify. A second 
layer containing 0.25% agar in McCoys medium with 
5,000 ATRA treated HT29 cells / well was poured over 
the first layer of agar and allowed to solidify. When the 
second layer had solidified, McCoys medium was added 
to each well. For ATRA treated SW480 cells, the same 
procedure was followed as with the HT29 cells except 
for the use of L15 medium. Medium was changed every 
two days and cultures were allowed to grow for two 
weeks before being fixed and visualized on either a phase 
microscope if stained with 0.05% crystal violet or a 
fluorescent microscope if stained with a green fluorescent 
nuclear acid stain called Syto13 (Life Technologies, 
Carlsbad, CA cat # S7575).
Colonosphere assay
This assay was done according to our previously 
published protocol [12]. Basically, untreated and liarozole 
dihydrochloride treated HT29 cells were plated at a cell 
density of 200 cells/100μl of sphere formation medium 
and allowed to grow for 14 days. The total number of 
spheres per well were counted and the average numbers 
are presented in the graph.
Statistical analysis
All statistics were performed using Student’s t-test 
using Microsoft excel or one-way ANOVA using Graph 
Pad Prism software analysis.
CONCLUSIONS
In the quest to understand how ALDH+ SCs 
become overpopulated in cancer, this is among the first 
reports looking at the relationship between ALDH+ 
colonic SCs and retinoid receptors – RAR and RXR – 
and the co-localization of the receptors with ALDH. In 
conclusion, our results indicate that RA signaling regulates 
the dynamics of colonic CSCs and dysregulation of RA 
signaling contributes to CRC development. Thus, RA 
signaling offers a potential therapeutic target by inducing 
increased differentiation and apoptosis of colonic CSCs. 
This approach would employ RA agents that restore 
normal tissue homeostasis rather than trying to induce 
cytotoxicity as occurs with conventional systemic anti-
cancer treatments. Indeed, ATRA has been used as a 
differentiation agent for in vitro studies and for clinical 
cancer therapy [26–29]. For example, in breast cancer, it 
has been shown that ATRA induced cell differentiation 
in breast cancer cells and sensitized the ALDH+ breast 
cancer cells to chemotherapeutics [30–33]. In acute 
promyelocytic leukemia, RA agents are highly efficacious 
and even curative [34]. Our findings – that RA signaling 
acts through ALDH+ colonic CSCs and that ATRA 
can decrease SC numbers and sphere formation via 
differentiation – may provide clues as to how RA agents 
in combination with other SC-targeting therapies may 
be developed into new more effective approaches to the 
treatment of advanced CRC.
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